US8198242 — Variants of C-type natriuretic peptide
Method of Use · Assigned to Biomarin Pharmaceutical Inc · Expires 2030-06-11 · 4y remaining
What this patent protects
This patent protects variants of C-type natriuretic peptide and methods of making them for use as therapeutic agents in treating bone-related disorders and vascular smooth muscle disorders.
USPTO Abstract
The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3927 |
— | vosoritide |
U-3927 |
— | vosoritide |
U-3927 |
— | vosoritide |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.